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Summary All-trans retinoic acid (ATRA) has been previously shown to inhibit the proliferation of some human ovarian carcinoma cell lines,
and this inhibition was accompanied by cellular changes that were indicative of differentiation (Caliaro et al, 1994). In this work, a
pretreatment of these adenocarcinoma cells with ATRA, for their respective doubling time, enhanced cisplatin (CDDP) cytotoxicity in the cell
lines that were sensitive to its antiproliferative effect, but not in the ATRA-resistant ones. Results were assessed using median effect analysis
in two ATRA-sensitive cell lines (OVCCR1 and NIHOVCAR3 cells) and in one ATRA-insensitive cell line (IGROV1 cells). Synergy between
these two agents was observed only in cells sensitive to ATRA, regardless of their relative sensitivity to CDDP. Potential mechanisms for this
synergy were investigated. ATRA did not increase the cellular platinum content, did not decrease the cellularglutathione and had no influence
on the metallothionein IIA mRNA levels in NIHOVCAR3 cells. Moreover, the protein kinase C (PKC) activity was modulated by this
differentiating agent in all cell lines tested, indicating thatthis activity was not directly involved in this potentiation. However, an ATRA inhibition
of glutathione-S-transferase activity associated with an increase in the total DNA adducts formation could explain the potentiation of the
CDDP cytotoxicity observed in NIHOVCAR3 cells. Finally, the ATRA modulation of the epidermal growth factor (EGF) receptor mRNA level
could also be implicated in this synergy.
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Although cisplatin (CDDP) is a valuable cytotoxic agent in the
treatment ofovarian carcinoma (Ozols et al, 1991), its clinical effi-
ciency tends to be limited by the frequent progression of the
tumour to a CDDP-resistant state (Behrens et al, 1987). Apotential
idea for improving treatment of ovarian adenocarcinoma is by
enhancing the cytotoxicity of CDDP in an attempt to reverse
intrinsic or acquired resistance. Intraperitoneal administration of
CDDP, which increases the concentration ofthis compound 12- to
15-fold attumoral level (Howell etal, 1991), and combination with
conventional chemotherapeutic agents have shown to be promising
but are limited by major toxicity towards normal cells. In the
absence ofa better understanding ofthis resistance, various agents
designed to reduce it have been tested in vitro. Examples include
EGF (Christen et al, 1990), buthionine sulphoximide (Andrews et
al, 1988; Hirata et al, 1993) and protein kinase C modulators
(Hofmann et al, 1988; Isonishi et al, 1990; Basu et al, 1994).
An alternative therapeutic approach to ovarian carcinoma could
be the use of agents that induce cellular differentiation, such as
retinoids. They include natural as well as synthetic derivatives of
vitamin A and have been shown to exert profound effects on the
proliferation and differentiation of various cell types (Sporn et al,
1983). All-trans retinoic acid (ATRA) induces differentiation of
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diverse tumour cell lines in vitro (Schiller et al, 1994). Moreover,
patients with acute promyelocytic leukaemia have been found to
enterremission after oral administration ofATRA (Castaigne et al,
1990). We have previously reported that ATRA has a dose-depen-
dent and reversible antiproliferative action in four human ovarian
carcinoma cell lines (Caliaro et al, 1994). The morphological and
biochemical changes associated with this antiproliferative effect
were consistent with the induction ofa differentiation pathway.
ATRA has been shown to increase the sensitivity of a murine
embryonal carcinoma cell line to CDDP (Guchelaar et al, 1993)
and to potentiate the cytotoxicity of CDDP, etoposide and
bleomycin in a human ovarian teratocarcinoma (Le Ruppert et al,
1992). Furthermore, the combination of ATRA and CDDP has
been reported to be beneficial in the treatment of head and neck
tumours (Sacks et al, 1995). Fenretinide, a synthetic retinoid, has
also been shown to enhance the anti-tumour activity of CDDP
against a human ovarian carcinoma cell line xenografted in nude
mice (Formelli et al, 1993).
In the present study, we evaluated the nature of interactions
between ATRA and CDDP on various ovarian carcinoma cell lines
and attempted to determine the molecular mechanisms underlying
the modulation ofCDDP cytotoxicity by this retinoid.
MATERIALS AND METHODS
Drugs, chemicals, enzymes and molecular reagents
All the agents used in this work were purchased from Sigma
(Coger, Paris, France).
333334 MJ Caliaro et al
Cell lines
The human ovarian carcinoma cell lines used for this study
included five serous cell lines: NIHOVCAR3 (ATCC, HTB161),
OVCCR, (Jozan et al, 1992), 2008 and its cisplatin-resistant
subline 2008/C13* (a generous gift from Dr Stephen Howell,
University of California, San Diego, La Jolla, CA USA) and
A2780 (Behrens et al, 1987) and two endometrioid cell lines:
IGROV, (a generous gift from Dr J Benard, Villejuif, France) and
SKOV3 (ATCC, HTB77).
The cells were grown in RPMI-1640 medium supplemented
with 5% fetal calf serum (FCS), 2 mM glutamine (Seromed,
Polylabo, Strasbourg, France), 2 ng ml-' epidermal growth factor
(Boehringer Mannheim, Germany) and 5 gg ml-' insulin in humid-
ified 5% carbon dioxide/95% air at 370C.
CDDP cytotoxicity assays
CDDP cytotoxicity was measured by clonogenic assay on plastic.
The cells were plated to obtain about 200 control colonies for each
cell line. After plating, the cells were treated for a single doubling
time with a suitable concentration ofATRA, based on their respec-
tive sensitivities to this agent (IC30). Then, they were incubated
for 1 h with various concentrations of CDDP. The cells were
washed and left to form colonies in the presence of the same
concentration of ATRA.
The time course of the ATRA effect was evaluated in experi-
ments on NIHOVCAR3 cells. Two days after plating, the cells
were treated with ATRA for different times exposure (0, 6, 12, 24,
and 48 h) and then with CDDP IC50 for h. The medium was then
renewed, and they were left to form colonies in the presence
of ATRA.
Median effect analysis
Median effect analysis was used to establish the interactions
between ATRA and CDDP only in OVCCR,,NIHOVCAR3 and
IGROV, cells, according to Chou and Talalay (1984). The combi-
nation index (CbI) was determined using a clonogenic assay on
plastic at increasing level ofcell kill with the same schedule as for
CDDP cytotoxicity assays except that ATRA and CDDP were
combined in a fixed concentration ratio corresponding to the ratio
ofthe individual IC50 (w/w) for each cell line (ATRA-CDDP), i.e.
3:10 for OVCCR, cells and 1:10 for NIHOVCAR3 cells. For
IGROVI cells, the ratio was fixed to 300:25.
For the molecular mechanism studies ofATRA action on CDDP
sensitivity, only two cell lines were used - one sensitive to its
antiproliferative effect, NIHOVCAR3, and one insensitive to it,
IGROVI cells. The concentration used was 106 M ATRA.
Platinum accumulation
For platinum accumulation, the cells growing in the log phase in
10-cm-diameter Petri dishes were treated during one doubling
time with 106 M ATRA. They were then incubated with their
IC50 CDDP. At the end of this incubation, the IGROV, and
NIHOVCAR3 cell lines were harvested by trypsinization, rinsed
with phosphate-buffered saline (PBS), counted and centrifuged at
300 g. The final pellet was reconstituted with water and frozen at
-20°C. On the day of assay, the cells were thawed and disrupted by
sonication, and the platinum concentration was determined in the
samples by flameless atomic absorption spectrophotometry.
Total GSH concentration and glutathione S-Transferase
(GST) activity
IGROVI and NIHOVCAR3 cells were incubated with 10- M
ATRA for their respective doubling time. They were then changed
for a new medium with ATRA (Oh). Glutathione (GSH) and GST
activity were determined in cytosolic fractions from lysed cells at
0, 4, 8, 12, 24 and 48 h after the second addition of ATRA, using,
respectively, the kinetic assay of Akerboom et al (1981) and the
method described by Habig et al (1974) as previously described
(Nehme et al, 1994).
Expression of metallothionein mRNA
NIHOVCAR3 and OVCCR, cell lines were treated with 106 M
ATRA. After 0, 4, 6, 12, 24 and 48 h exposure, total RNA was
isolated from the cells, using a one-step acid guanidinium iso-
thiocyanate-phenol-chloroform method and separated in 1.2%
agarose gels. RNA was transferred to a nylon membrane (Hybon
N, Amersham) and fixed by UV, and the hybridization was
conducted as previously described by Nehme et al (1994).
Pt-DNA adducts formation and repair
Cells were grown in 10-cm-diameter Petri dishes. Two days later,
they were incubated with 106 M ATRA. One day later, they
received 0.2gCi ml-' [3H]thymidine for 24 h. At 48 h ATRA incu-
bation, all the cells received lOjg ml-' CDDP for 1 h. Cells were
harvested at the following time points: 0, 24 and 48 h later. Total
cellular DNA was extracted, according to the method of Miller et
al (1988), and the experiments were made as previously described
(Nehme et al, 1994).
PKC activity involvement in CDDP sensitization
In this study, we looked for the possible modulation of PKC in
these cell lines, using TPA (12-O-tetradecanoyl phorbol 13-
acetate) as a control agent. The consequence ofthis modulation on
the sensitization to CDDP was also analysed. To do this, the
NIHOVCAR3 cells were treated by 107M TPA for 5 min, 1 h or 24
h before incubation with IC50 CDDP. The subsequent experimental
conditions ofclonogenic assay were the same as forATRA-CDDP.
For the PKC activity assay, NIHOVCAR3 and IGROV, cell
lines were used. All experiments were carried out in the exponen-
tial growth phase. Cells were incubated with 10-M ATRA or 10-7M
TPA for 2, 5, 10, 20, 30, 60 min, 24 and 48 h. After these incuba-
tions, the cells were washed with 0.9% sodium chloride, scraped
off with a rubber policeman and centrifuged at 300 g for 10 min.
The pellet was kept at -70°C until assay. The PKC activity was
evaluated on cytosolic- and Triton x 100- extracted membranes
after partial purification on DE52 (Whatman, STP, Paris, France)
columns with Gibco BRL kit, according to the manufacturer's
recommendations.
Expression of EGF receptor (EGFR) mRNA under ATRA
treatment
This expression was studied by reverse transcriptase-polymerase
chain reaction (RT-PCR). After plating, the two cell lines were
pretreated by 106 M ATRA for various times and the RNA
isolated. Oligonucleotide primers complementary to EGFR
mRNA (antisense primer) and sense primer were synthesized by
Genset (France) from the following sequence:
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Table 1 Sensitivity of various ovarian carcinoma cell lines to ATRA, CDDP and the combination of these two agents
Cell line Histological Doubling time ATRA IC CDDP IC ,CDDP Potentiationb
type (h) sensitivitya control ATRA
(IC50M) (jg ml-) pretreatment
(jig mi-')
A2780 Serous 24 >5x10-5 0.45 ± 0.02 0.60 ± 0.03 No
2008 Serous 30 >5x10-5 0.72 ± 0.04 0.70 ± 0.02 No
IGROV, Endometrioid 24 >5x10-5 0.38 ± 0.02 0.44 ± 0.03 No
2008/C13* Serous 24 5x105 4.8 ± 0.3 3.2 ± 0.4 1.5
SKOV3 Endometrioid 24 5x10-5 4 ± 0.4 2.8 ± 0.2 1.4
NIHOVCAR3 Serous 48 5x10-7 0.28 ± 0.03 0.15 ± 0.02 1.8
OVCCR, Serous 72 5x10-7 1.00 ± 0.05 0.4± 0.1 2.5
aAccording to Caliaro et al (1994). 5Potentiation was expressed as the ratio of the IC50 values of control and pretreated cells. The IC50 values for each cell line
represent the average of four independent experiments carried out in triplicate.
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Figure 1 Time course of CDDP sensitization by ATRA in NIHOVCAR3cells.
Two days after plating, the cells were pretreated for different times of
exposure to 10-7 M ATRA (0, 6, 12, 24, or 48 h), before a 1-h exposure to
CDDP (0.3 jg ml-') as described in Materials and methods. Each histogram
represents the percentage of control survival. The line drawn on the
histogram shows the expected additive result of the ATRA-CDDP
combination, calculated from the corresponding ATRA and CDDP survival.
The results are means ± s.d. of three separate experiments. E, CDDP;
*, ATRA; U, ATRA+CDDP; -0-, additive effect
sense primer:
antisense primer:
5'-T-lTCGATACCCAGGACCAAG-3'
5'-AATATTCTTGCTGGATGCGT-3'
3-
2-
1
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Figure 2 Nature of interaction between ATRA and CDDP in three human
ovarian carcinoma cell lines. The combination index plots were calculated,
according to the Chou and Talalay method, from the clonogenic assay
described in Materials and methods. Cbl >1 indicates an antagonism, Cbl <1
indicates a synergy. Each curve represents the average of four separate
experiments, using triplicate cultures from each data point. , OVCCR,;
-A-, NIHOVCAR3; -LI-, IGROV,
according to Heniford et al (1993), which give a 201-bp product. A
semiquantification was made by simultaneous amplification of
GAPDH, according to Dukas et al (1993). The PCR products were
separated on 7.5% polyacrylamide gels, fixed, dried and exposed
to Hyperfilm MP at - 20°C. The results were quantified using a
Kodak DCS 200 densitometer.
RESULTS
Influence of ATRA on CDDP cytotoxicity
Cytotoxicity was evaluated against seven cell lines in a clonogenic
assay on plastic. The IC50 for CDDP ranged from 0.38 to 4.8 ,ug
ml-l for the different cell lines (Table 1). Likewise, differences in
sensitivity to the antiproliferative effect of ATRA (Caliaro et al,
1994) were observed; three cell lines were insensitive to ATRA,
two had weak sensitivity and only NIHOVCAR3and OVCCR, had
an IC50 of5xjO-7M.
Table 1 shows the results obtained with different cell lines.
ATRA enhances their CDDP sensitivity, after a doubling time
before treatment, but only in cells that are sensitive to its antipro-
liferative effect. The most sensitive cell lines are NIHOVCAR3
and OVCCR,; ATRA reduces their CDDP IC50 1.8- and 2.5-fold
respectively. It was noteworthy that the IC50 ofthe 2008/C13* cell
line, a variant resistant to CDDP and sensitive to ATRA, decreases
from 4.8 to 3.2 gg ml-' in the clonogenic assay.
Time course of sensitization to CDDP by ATRA
NIHOVCAR3 cells were pretreated with different times of expo-
sure to 10-7 M ATRA (0, 6, 12, 24, 48 h) before 1 h of exposure to
0.3 jig ml' CDDP. Figure 1 shows that, in the absence of ATRA,
0.3 jig ml-' CDDP reduces the colonies' survival to 50%. A line
drawn on the experimental histograms indicates the additive
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Figure 3 The effect of ATRA on cellular GST activity. Cells were treated with 104 M ATRA for one doubling time (24 h for IGROV1 and 48 h for NIHOVCAR3
cells). They were then incubated in new medium with or without ATRA (0 h) for 4, 8, 12 and 24 h. GST activity was measured at each time point in the two cell
lines. The results were calculated as nmol of 1-chloro-2,4-dinitrobenzene (CDNB) conjugated per minute and per mg of protein, and expressed as the
percentage of corresponding control values. Each point represents the mean of eight experiments. Asterisks indicate significant difference from the control:
*P<0.05 and**P< 0.01 respectively
inhibition expected for the ATRA-CDDP combination. This was
calculated from the percentage survival obtained from each drug at
the corresponding times. This effect is only observed when cells
are treated with CDDP after incubation with ATRA. Under these
conditions, sensitization appeared after 12 h pretreatment with
ATRA, increased at 24 h and became stable at 48 h.
Nature of interaction between CDDP and ATRA
As ATRA enhances cellular CDDP cytotoxicity under our condi-
tions, we investigated the nature of interaction between these two
agents for two sensitive cell lines (OVCCR1 and NIHOVCAR3)
and for one insensitive cell line (IGROV,). Figure 2 shows that for
OVCCR, cells ATRA acts synergistically CDDP cytotoxicity in
the whole of the fraction affected (CbI <1). Whereas, in
NIHOVCAR3, a synergy is only observed when the fraction
affected is greater than 40%, and an antagonism is shown for
IGROV1 cells (CbI>1)
In the second part of this work, we studied the possible mecha-
nisms involved in this synergy, such as a modulation ofdrug accu-
mulation - either alterations in cellular detoxification systems or a
possible modulation of the DNA repair. We have also studied the
ATRA signal transduction pathway by assaying protein kinase C
(PKC) activity and EGF receptor expression. As the synergy is
more important for the highest concentration of CDDP in
NIHOVCAR3 cells, we have used 106 M ATRA for the biochem-
ical experiments.
Influence of ATRA on platinum accumulation
After I h CDDP exposure, cellular platinum accumulation in
NIHOVCAR3 cells pretreated for48 h was 0.41 ± 0.07 ng ofPt 10-6
cells vs 0.37 ± 0.03 ng ofPt 10-6cells (n=5) in the control cells. In
addition, no difference was observed in IGROV, cells 0.013 +
0.03 ng ofPt 10- cells vs 0.10 ± 0.03 ng ofPt l0" cells (n=5).
Effect of ATRA on cellular detoxification system
Cellular GSH contentand GSTactivity
To circumvent fluctuations in cellular levels of GSH and GST
activity owing to culture conditions in the control cells, we serially
determined these values with or without 10- M ATRA after
pretreatment with this agent for a cell doubling time.
No difference in GSH was observed after 48 h pretreatment of
NIHOVCAR3 cells with ATRA - 67 ± 12 (n=8) in the treated cells
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Figure 4 Total Pt-DNA adducts formation and removal in NIHOVCAR3 cells
after pretreatment with ATRA. The total Pt-DNA adducts were measured at
various times after a 1-h 10 9g ml-' CDDP incubation as in Materials and
methods: Each data point represents the mean of six experiments. Asterisks
indicate significant difference from the control cells: *P < 0.05 and **P <0.01
U, Control; U, ATRA
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Figure 5 Modulation of CDDP sensitivity and PKC activity by TPA in NIHOVCAR3 cells. (A) PKC activity. At various times after exposure to 10-7M TPA, the cells
were harvested, rinsed with PBS and frozen at - 800C until PKC activity assay, as described in Materials and methods. The results are expressed as the
percentage of the cytosolic-and membrane-associated PKC activities in controls, which were 158 ± 50 and 59 ± 35 (n=7) in NIHOVCAR3 cells and 52 ± 12 and
62 ± 10 (n=4) pmol of P min-' mg-' protein in IGROV1 cells The results represent the mean of four experiments. O, Cytosol; U, membrane. (B) CDDP
sensitivity. The cells were treated for 5 min, 1 h or 24 h with 10-7M TPA, washed and exposed for 1 h to 0.3 ,ug mi-' CDDP. After washing, they were left to form
colonies on plastic. The results are expressed as the percentage of the control survival. The line on the histograms represents the expected additive result of
the TPA-CDDP combination, calculated from the respective TPA and CDDP survival. The results are the mean ± s.d. of three separate experiments. O, TPA;
U, CDDP; 0, TPA+CDDP; -0-, additive effect
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Figure 6 The effect of ATRA on PKC activity in IGROV1 and NIHOVCAR3 cell lines. The cells were treated as in the 'Material and methods' section, and the
results are expressed as the percentage of the control cytosolic and membrane PKC activities. The data represent the means ± s.d. of four experiments.
E, Cytosol; E, membrane
vs 51 ± 7 (n=8) nmol of GSH per mg of protein in controls. The
second ATRA addition was followed by a transient but significant
(30%) decrease in GSH level, which returned to the normal range
within 12 h. For GST activity, a decrease of 32% was noted after
48 h pretreatment (268 ± 59 vs 391 ± 66 nmol of 1-chloro-2,4-
dinitrobenzene (CDNB) per mgprotein in controls; P <0.05) andtotal
GST activity remained significantly lower (at 8 h,P <0.01) for 24 h.
InIGROVI cells, the changes in GSH level and GST activity were
not significant. To simplify the representation, we have only listed the
results on GST activity in Figure 3.
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Figure 7 Effect of 10-6 M ATRA on the expression of EGFR mRNA in human ovarian carcinoma cells. The expression was shown by RT-PCR as described in
'Materials and methods'. A semiquantified method was made by simultaneous amplification of GAPDH and EGFR. An autoradiogram was obtained in
NIHOVCAR3 cells (A) and in IGROV1 cells (B) at various times. C and Cl represent the results for the control cells at 0 and 48h respectively. Quantification of
these autoradiograms was made using a densitometer (C). -{-}, NIHOVCAR3; -4-, IGROV,
Influence ofATRA on the expression ofmetallothionein
mRNA
Expression of hMTIIA mRNA was higher in the OVCCR1 cells
than in the NIHOVCAR3 cell line, but incubation with ATRA for
48 h had no noticeable effect in either cell line (data not shown).
DNA platinum adducts formation under ATRA treatment
As the critical intracellular target for cisplatin is reported to be the
DNA, we examined the formation and the evolution of total plat-
inum-DNA adducts under ATRA treatment.
Figure 4 shows the data obtained in NIHOVCAR3 cells treated
as described in 'Materials and methods'. ATRA increases the total
DNA adducts formation in this cell line and this increase persists
for 48 h, whereas no modulation is observed in IGROV1 cells (6.8
+ 0.8 vs 7.02 ±1.4 ng of Pt per mg of DNA for control cells, data
not shown). It is interesting to note that no DNA repair in control
cells, estimated from the ratio of loss of platinum, could be
observed for 48 h in NIHOVCAR3 cells.
PKC activity involvement in sensitization to CDDP by
ATRA
Protein kinase C has been shown to be involved in sensitization of
cells to CDDP, but the exact mechanism (activation or inhibition)
remains to be elucidated. In this work, we looked for the modula-
tion of CDDP cytotoxicity using TPA, the principal PKC modu-
lator, and determined the kinetic activation of this kinase in
NIHOVCAR3 cells using this phorbol ester. We then investigated
the influence ofATRA.
It can be seen from Figure 5A that TPA altered PKC activity in
NIHOVCAR3 cells. A fast activation was observed during a 2-min
exposure to TPA followed by an inactivation for 5 min. Moreover,
in clonogenic assay, TPA leads potentiation of CDDP cytotoxicity
regardless of the time of pretreatment with this phorbol ester, i.e.
5 min, 1 h or 24 h (Figure 5B).
ATRA treatment had different effects in the two cell lines
(Figure 6). InIGROVI cells, which are insensitive to its antiprolif-
erative effect and for which no potentiation is obtained, there is
an increase in both cytosolic and membrane PKC activity at 30
min exposure to 1O0M ATRA, followed by a slow decrease. In
NIHOVCAR3 cells, there is a decrease in both cytosolic and
membrane PKC activity for 20 min, followed by an increase in
activity in the two fractions. In this cell line, PKC activity is stim-
ulated late by ATRA (at 24 h).
Modulation of EGF receptor expression under ATRA
treatment
A transient increase (2.6-fold) of EGFR mRNA level was
observed at 12 h (Figure 7A) in NIHOVCAR3 cells, whereas an
inhibition was reported for IGROVI cells as early as 12 h with a
maximum at 24 h (45%). This inhibition remains constant for 72 h
(Figure 7B). An increase (three-fold) is also observed for sensitive
OVCCR, cells at 24 h (data not shown).
DISCUSSION
In this study, we reported that the antiproliferative effect of the
retinoid ATRA is associated with its ability to increase CDDP
cytotoxicity in various human ovarian carcinoma cell lines in
vitro. Interestingly, it also enhanced CDDP cytotoxicity in the
CDDP-resistant cell line 2008/C 13*. These observations suggest
that ATRA might help overcome CDDP resistance and prolong
survival in patients with certain types of ovarian cancer. In fact,
the level of CDDP resistance that occurs in patients is quite low.
Howell et al (1991) have shown that the IC50 of resistant cells in
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vivo is less than twice that of parental cells before treatment with
CDDP. This weak resistant level is compatible with ATRA
capacity to increase CDDP cytotoxicity.
The combination effect of ATRA and CDDP treatment on
ovarian adenocarcinoma cell proliferation could be owing to an
enhancement ofCDDP cytotoxicity by ATRA or to an elevation of
the antiproliferative action of ATRA in the presence of CDDP.
Therefore, the potentiation of ATRA was only observed in
OVCCRI, NIHOVCAR3, 2008/C 13* and SKOV3 ovarian adeno-
carcinoma cells which are all responsive to the antiproliferative
effect of ATRA. These results support the hypothesis that ATRA
modulates CDDP cytotoxicity. This effect on ovarian carcinoma
cell proliferation was only observed when ATRA was added
before CDDP and for a duration corresponding to the doubling
time of the different ovarian adenocarcinoma cells. For
NIHOVCAR3 cells, the optimal effect was observed at48 h. These
results are in line with those previously reported for small-cell
lung cancer (Doyle et al, 1989), for an ovarian teratocarcinoma (Le
Ruppert et al, 1992), for a murine embryonal carcinoma cell line
(Guchelaar et al, 1993) and for epidermoid carcinoma (Sacks et al,
1995). Taken together, these observations suggest that ATRA
induces a cascade ofevents facilitating CDDP cytotoxicity.
The nature of the interaction evaluated according to the method
ofChou and Talalay (1984) was shown to have a synergistic effect
forOVCCR, and NIHOVCAR3 cells, whereas an antagonism was
observed with IGROVI cells. More interesting, in OVCCR, cells,
this synergy was observed for all the fractions affected, whereas in
NIHOVCAR3 cells it was only obtained for the high fraction
affected. The same type ofsynergy has also been obtained with the
association between INFy and CDDP (Nehme et al, 1994) in the
same cell lines and for IL-la-CDDP for NIHOVCAR3 cells
(Benchekroun et al, 1993). Moreover, we can note that this synergy
is more important, when it is present, in NIHOVCAR3 than in
OVCCRI cells whatever the association, i.e. ATRA-CDDP or
INFy-CDDP. These results suggest that interaction between CDDP
and biological response modifiers could be cell line dependent.
The enhancement of CDDP cytotoxicity by ATRA could stem
from a variety ofmolecular mechanisms.
One possibility is that the increase in intracellular accumulation
of CDDP leads to sensitization. IL-la (Benchekroun et al, 1993),
forskolin (Mann et al, 1991) and amphotericin B (Morikage et al,
1993) all increase platinum accumulation and enhance the cyto-
toxic effect of CDDP. In this present work, we found that ATRA
does not modify the platinum accumulation regardless ofthe sensi-
tivity of the cells to this agent. Similarly, ATRA was not found to
alter platinum accumulation in a murine embryonal carcinoma cell
line (Guchelaar et al, 1993).
The second possibility is that ATRA has an influence on cell
detoxification systems, such as GSH and GST activity and metal-
lothionein. Indeed, the intracellular levels of GSH and GST have
been reported to influence sensitivity to CDDP (Chen et al, 1989).
We only observed a transient decrease in the GSH content after
treatment ofNIHOVCAR3 cells with ATRA. This would probably
not be sufficient to potentiate CDDP cytotoxicity as it has been
shown that only prolonged GSH depletion could sensitize human
ovarian carcinoma cells to CDDP cytotoxicity (Andrews et al,
1988). We found that ATRA decreased GST activity in
NIHOVCAR3 cells, whereas it had no influence on this activity in
IGROV, cells. GSTi is the only isoenzyme of GST expressed in
these ovarian cell lines (Nehme et al, 1995), and it has been
reported that GSTir transcription in simian virus-transformed
human keratinocytes is regulated by retinoids (Xia et al, 1993).
The correlation between the increase in CDDPcytotoxicity and the
decrease in GST activity found in NIHOVCAR3 cells is in favour
of a role of GST modulation in the sensitization of ovarian carci-
noma cells to CDDP.
A third possibility could be the interaction with the DNA repair
ofcells treated with CDDP. In this study, ATRA increased the total
DNA adduct number at 0, 24 and 48 h after CDDP treatment, and
this increase remained constant throughout the experiment. These
results suggest that NIHOVCAR3 cells do not repair its DNA
adducts for 48 h and that the kinetics ofrepair are not affected by
ATRA. It was reported that the persistence of an increased number
of adducts could be involved in the sensitivity of cells to CDDP
(Bedford et al, 1988). Moreover, a correlation was shown between
the number of adducts in leucocytes and monocytes DNA of
patients treated with CDDP and the clinical response to it (Reed et
al, 1987). All these results confirm the hypothesis that the
increased number of total DNA adducts (1.5-fold) in ATRA-
treated cells could be implicated in the potentiation ofCDDP cyto-
toxicity.
A fourth possibility is an involvement of PKC in the ATRA-
induced increase in CDDP toxicity. Indeed, several studies have
indicated a role for PKC activity in the sensitization to CDDP
(Hofmann etal, 1988; Isonishi et al, 1990; Hirata etal, 1993; Basu
et al, 1994). An inhibition or an activation ofPKC in CDDP sensi-
tization appears to depend on cell type. There is recent evidence
for a role of PKC in the signalling of ATRA-induced terminal
differentiation before activation of the nuclear receptor RAR,
(Kurie et al, 1993a). In addition, there is evidence for cooperation
between the signalling pathways of retinoids and PKC activators
(Kurie et al, 1993b, Bouzinba-Segard et al, 1994). We therefore
have investigated the possible implication of PKC in ATRA-
enhanced CDDP cytotoxicity. We found that PKC was activated
by ATRA regardless ofthe sensitivity ofthe cell line to its antipro-
liferative effect. However, the time course of the activation
differed between cell lines (compare NIHOVCAR3 and IGROV,)
and in NIHOVCAR3 cells differed from that induced by TPA.
These results are not consistent with a direct involvement of PKC
in the CDDP sensitization by ATRA in these cell lines.
The last possibility could be the EGFR pathway. Indeed, ATRA
increases the mRNA level of this receptor in NIHOVCAR3 and
OVCCRI cells, and this modulation is accompaniedby a sensitiza-
tion of these cell lines to CDDP, whereas in IGROVI cells an
opposite effect is observed. These results suggest a possible impli-
cation ofthe EGFR pathway in the potentiation ofCDDP cytotox-
icity in these cells. Although the modulation of EGFR protein
remains to be studied, similar results were obtained in the tumour
necrosis factor (TNF)-resistant cell line ME180 R which has an
increasing sensitivity to CDDP (Nishikawa etal, 1992) and a more
important expression ofEGF receptor protein. Moreover, Christen
et al (1990) have also shown that the CDDP sensitivity ofcells are
dependent upon the number ofEGF receptors.
In this study, we have shown that a pretreatment with ATRA
potentiates the CDDP cytotoxicity of cells sensitive to its antipro-
liferative effect. The molecular mechanism involved in this
synergy is probably multifactorial. The ability of ATRA to
decrease GST activity and to increase the total DNA adducts might
contribute directly to the enhancement of CDDP cytotoxicity.
Moreover an implication of the EGFR pathway might also be
considered. Although the exact mechanism ofthis ATRA potentia-
tion is not totally elucidated, the present results are in line with
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those of Formelli et al (1993) who suggested in an in vivo study
that differentiation-inducing agents, such as all-trans retinoic acid,
might enhance the therapeutic efficiency of CDDP in human
ovarian adenocarcinoma.
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